Get David Sinclair on Dwarkesh Podcast

David Sinclair matters today because the cellular reprogramming work he helped pioneer is finally moving into humans, with Life Biosciences planning first-in-human trials of its OSK-based ER-100 for two optic neuropathies in early 2026. If those trials show even partial vision restoration, it could reset the debate over whether aging processes are tractable in living patients right now, not in some distant future.

At the same time, the FDA reversed course in late 2025 to allow NMN back on the U.S. supplement market, a compound Sinclair popularized, which puts his ideas about NAD metabolism and consumer longevity products back in the spotlight. Pair that momentum with mainstream coverage of reprogramming’s clinical push and you have a rare window where policy, biotech, and public interest are aligning.

There is controversy to press him on, including criticism about past overhype and conflicts of interest, which makes a rigorous, well-researched conversation on Dwarkesh’s show especially timely and valuable. By our search, he has not appeared on the Dwarkesh Podcast before, so this would be a first encounter for that audience with the field’s most polarizing advocate.

If you want this pivotal conversation to happen while trials begin and rules shift, back this nomination today.